These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 15498365)

  • 1. Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model.
    Yu MY; Gao RL; Jiang J; Cheng SJ; Yuan JQ; Wang CN; Zheng JG; Meng L; Zi ZJ
    Chin Med J (Engl); 2004 Oct; 117(10):1459-63. PubMed ID: 15498365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions.
    Vetrovec GW; Rizik D; Williard C; Snead D; Piotrovski V; Kopia G
    Catheter Cardiovasc Interv; 2006 Jan; 67(1):32-7. PubMed ID: 16342216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model.
    Kipshidze NN; Porter TR; Dangas G; Yazdi H; Tio F; Xie F; Hellinga D; Wolfram R; Seabron R; Waksman R; Abizaid A; Roubin G; Iyer S; Colombo A; Leon MB; Moses JW; Iversen P
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):389-94. PubMed ID: 15736246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental efficacy of an everolimus eluting cobalt chromium stent.
    Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.
    Wiemer M; Seth A; Chandra P; Neuzner J; Richardt G; Piek JJ; Desaga M; Macaya C; Bol CJ; Miquel-Hebert K; De Roeck K; Serruys PW
    Am Heart J; 2008 Oct; 156(4):751.e1-7. PubMed ID: 18926156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
    Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.
    Hausleiter J; Kastrati A; Wessely R; Dibra A; Mehilli J; Schratzenstaller T; Graf I; Renke-Gluszko M; Behnisch B; Dirschinger J; Wintermantel E; Schömig A;
    Eur Heart J; 2005 Aug; 26(15):1475-81. PubMed ID: 15975990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of lesions with a high risk of stenosis. Comparative study in 300 patients of rapamycin- and Paclitaxel-eluting polymer-based stents, and bare metal stents].
    de la Torre Hernández JM; Sainz Laso F; Ruisánchez C; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2005 Mar; 58(3):262-9. PubMed ID: 15766448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biocompatibility of tetramethylpyrazine-eluting stents in normal porcine coronary arteries.
    Ma GS; Chen LJ; Chen Z; Ding S; Shen CX; Feng Y
    Biomed Pharmacother; 2008 Feb; 62(2):125-9. PubMed ID: 17764890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement.
    Neumann FJ; Desmet W; Grube E; Brachmann J; Presbitero P; Rubartelli P; Mügge A; Di Pede F; Füllgraf D; Aengevaeren W; Spedicato L; Popma JJ
    Circulation; 2005 Apr; 111(16):2107-11. PubMed ID: 15851617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
    Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
    Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelialization of sirolimus-eluting stents with slow and extended drug release in the porcine overstretch model.
    Frey D; Billinger M; Meier P; Beslac O; Grossenbacher R; Hänni B; Hess OM
    J Invasive Cardiol; 2008 Dec; 20(12):631-4. PubMed ID: 19057024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.